Cargando…

Oncologic outcomes in patients with nonurothelial bladder cancer

INTRODUCTION: We aimed to evaluate the relative prognostic impact of the most common variant histologies on disease-specific survival (DSS) in patients undergoing radical cystectomy. MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Result database was used to identify patients who unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Sanjay G., Weiner, Adam Benjamin, Keegan, Kirk, Morgan, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769248/
https://www.ncbi.nlm.nih.gov/pubmed/29343911
http://dx.doi.org/10.4103/iju.IJU_115_17
_version_ 1783292863478497280
author Patel, Sanjay G.
Weiner, Adam Benjamin
Keegan, Kirk
Morgan, Todd
author_facet Patel, Sanjay G.
Weiner, Adam Benjamin
Keegan, Kirk
Morgan, Todd
author_sort Patel, Sanjay G.
collection PubMed
description INTRODUCTION: We aimed to evaluate the relative prognostic impact of the most common variant histologies on disease-specific survival (DSS) in patients undergoing radical cystectomy. MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Result database was used to identify patients who underwent radical cystectomy for bladder cancer from 1990 to 2007. Patients with urothelial cell carcinoma (UCC), squamous cell carcinoma (SCC), adenocarcinoma (AC), sarcoma, small cell carcinoma, signet ring carcinoma, and spindle cell carcinoma were included in the study. Multivariable analysis was performed using Cox proportional hazards model to assess independent predictors of disease-specific survival (DSS). Mortality rates were estimated using Kaplan–Meier analyses. RESULTS: A total of 14,130 patients met inclusion criteria with the following histologies: UCC (90.1%), SCC (4.6%), AC, (2.3%), sarcoma (0.8%), small cell carcinoma (0.8%), signet ring carcinoma (0.5%), and spindle cell carcinoma (0.9%). Three-year DSS was most favorable in patients with UCC (63.7%; 95% confidence interval [62.9%–64.8%]) and AC (65.3% [59.3%–70.6%]), whereas 3-year DSS was the least favorable for small cell carcinoma (41.6% [31.3%–51.6%]) and sarcoma (45.4% [35.1%–55.1%]). In the multivariable analysis, independent predictors of DSS were age, marital status, grade, T-stage, N-stage, and variant histology. With respect to UCC, there was an increased risk of disease-specific death associated with all variants except AC. Sarcoma and spindle cell carcinoma were associated with the highest risk of death. CONCLUSIONS: With the exception of AC, the most common variant bladder cancer histologies are all independently associated with worse DSS relative to UCC in patients undergoing radical cystectomy.
format Online
Article
Text
id pubmed-5769248
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-57692482018-01-17 Oncologic outcomes in patients with nonurothelial bladder cancer Patel, Sanjay G. Weiner, Adam Benjamin Keegan, Kirk Morgan, Todd Indian J Urol Original Article INTRODUCTION: We aimed to evaluate the relative prognostic impact of the most common variant histologies on disease-specific survival (DSS) in patients undergoing radical cystectomy. MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Result database was used to identify patients who underwent radical cystectomy for bladder cancer from 1990 to 2007. Patients with urothelial cell carcinoma (UCC), squamous cell carcinoma (SCC), adenocarcinoma (AC), sarcoma, small cell carcinoma, signet ring carcinoma, and spindle cell carcinoma were included in the study. Multivariable analysis was performed using Cox proportional hazards model to assess independent predictors of disease-specific survival (DSS). Mortality rates were estimated using Kaplan–Meier analyses. RESULTS: A total of 14,130 patients met inclusion criteria with the following histologies: UCC (90.1%), SCC (4.6%), AC, (2.3%), sarcoma (0.8%), small cell carcinoma (0.8%), signet ring carcinoma (0.5%), and spindle cell carcinoma (0.9%). Three-year DSS was most favorable in patients with UCC (63.7%; 95% confidence interval [62.9%–64.8%]) and AC (65.3% [59.3%–70.6%]), whereas 3-year DSS was the least favorable for small cell carcinoma (41.6% [31.3%–51.6%]) and sarcoma (45.4% [35.1%–55.1%]). In the multivariable analysis, independent predictors of DSS were age, marital status, grade, T-stage, N-stage, and variant histology. With respect to UCC, there was an increased risk of disease-specific death associated with all variants except AC. Sarcoma and spindle cell carcinoma were associated with the highest risk of death. CONCLUSIONS: With the exception of AC, the most common variant bladder cancer histologies are all independently associated with worse DSS relative to UCC in patients undergoing radical cystectomy. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC5769248/ /pubmed/29343911 http://dx.doi.org/10.4103/iju.IJU_115_17 Text en Copyright: © 2017 Indian Journal of Urology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Patel, Sanjay G.
Weiner, Adam Benjamin
Keegan, Kirk
Morgan, Todd
Oncologic outcomes in patients with nonurothelial bladder cancer
title Oncologic outcomes in patients with nonurothelial bladder cancer
title_full Oncologic outcomes in patients with nonurothelial bladder cancer
title_fullStr Oncologic outcomes in patients with nonurothelial bladder cancer
title_full_unstemmed Oncologic outcomes in patients with nonurothelial bladder cancer
title_short Oncologic outcomes in patients with nonurothelial bladder cancer
title_sort oncologic outcomes in patients with nonurothelial bladder cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769248/
https://www.ncbi.nlm.nih.gov/pubmed/29343911
http://dx.doi.org/10.4103/iju.IJU_115_17
work_keys_str_mv AT patelsanjayg oncologicoutcomesinpatientswithnonurothelialbladdercancer
AT weineradambenjamin oncologicoutcomesinpatientswithnonurothelialbladdercancer
AT keegankirk oncologicoutcomesinpatientswithnonurothelialbladdercancer
AT morgantodd oncologicoutcomesinpatientswithnonurothelialbladdercancer